This document contains a series of case reports describing the use of PROMOGRAN® and PROMOGRAN PRISMA® (Systagenix) on patients with non-healing chronic wounds with elevated protease activity (EPA), assessed using a WOUNDCHEK™ Protease Status (Systagenix) test. All patients were treated for a minimum of four weeks and the decision to continue with PROMOGRAN®/PROMOGRAN PRISMA® was based on continual assessment. A formal assessment was performed weekly, although patients were instructed to carry out dressing changes more regularly in accordance with product labelling.
Supported by KCI – An Acelity Company
